Annual report pursuant to Section 13 and 15(d)

Reverse Merger - Additional Information (Detail)

v3.8.0.1
Reverse Merger - Additional Information (Detail)
$ / shares in Units, $ in Thousands
 12 Months Ended
Aug. 17, 2017
USD ($)
Aug. 01, 2017
Right
$ / shares
shares
Jan. 05, 2015
Dec. 31, 2017
USD ($)
shares
Dec. 31, 2016
shares
Business Acquisition [Line Items]          
Common stock, shares outstanding | shares       11,947,932 21,230
Contingent value rights recovery | $       $ 200  
OncoGenex Pharmaceuticals, Inc [Member]          
Business Acquisition [Line Items]          
Reverse stock split ratio   0.0909 0.0909    
Share price   $ 4.62      
Common stock, shares outstanding | shares   2,736,703      
Number of contingent value rights to be issued for each share of common stock outstanding | Right   1      
Contingent value rights recovery | $ $ 200        
OncoGenex Pharmaceuticals, Inc [Member] | Contingent Value Rights [Member]          
Business Acquisition [Line Items]          
Combined company acquisition period results   5 years      
Aggregate consideration distributed to the holders, consideration received percent   80.00%      
OncoGenex Pharmaceuticals, Inc [Member] | Warrant [Member]          
Business Acquisition [Line Items]          
Share price   $ 4.62      
OncoGenex Pharmaceuticals, Inc [Member] | Warrant [Member] | Minimum [Member]          
Business Acquisition [Line Items]          
Volatility rate   90.33%      
Risk-free interest rate   1.32%      
Expected lives   1 year 10 months 28 days      
OncoGenex Pharmaceuticals, Inc [Member] | Warrant [Member] | Maximum [Member]          
Business Acquisition [Line Items]          
Volatility rate   106.08%      
Risk-free interest rate   1.53%      
Expected lives   3 years 2 months 27 days      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member]          
Business Acquisition [Line Items]          
Share price   $ 4.62      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Minimum [Member]          
Business Acquisition [Line Items]          
Volatility rate   97.23%      
Risk-free interest rate   1.31%      
Expected lives   1 year 9 months 25 days      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Maximum [Member]          
Business Acquisition [Line Items]          
Volatility rate   106.63%      
Risk-free interest rate   1.54%      
Expected lives   3 years 3 months 22 days